JG
Therapeutic Areas
Onco3R Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| SIK | Autoimmune diseases | Phase 1 |
| FGFR3 | Bladder cancer | Phase 1/2 |
| SMARCA2 | Lung cancer | Preclinical |
| P53 | Solid tumors | Preclinical |
| Undisclosed | Immuno-oncology | Preclinical |
Leadership Team at Onco3R Therapeutics
PR
Pierre Raboisson
Chief Executive Officer
FG
François Gonzalvez
Chief Scientific Officer
GP
Guy Peeters
Chief Financial Officer
PP
Pieter Peeters
Chief Technology & Operations Officer
SV
Sandrine Vendeville
VP, Head of Medicinal Chemistry
JK
Joost Kolkman
VP, Head of Biologics
FK
Fabrice Kolb
VP, Head of Immunology
LB
Lawrence Blatt
Chairman of the Board